MIRA

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.07
Percentage change -5.60	%

Peers: CRON TLRY CARA CGC ACB IIPR VFF MNMD

Index	-	P/E	-	EPS (ttm)	-0.73	Insider Own	27.00%	Shs Outstand	16.27M	Perf Week	16.83%
Market Cap	19.54M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	-2.19%	Shs Float	12.09M	Perf Month	4.42%
Income	-11.24M	PEG	-	EPS next Q	-0.14	Inst Own	6.76%	Short Float	5.84%	Perf Quarter	-5.60%
Sales	0.00M	P/S	-	EPS this Y	-13.21%	Inst Trans	34.62%	Short Ratio	2.05	Perf Half Y	-16.31%
Book/sh	0.22	P/B	5.37	EPS next Y	10.00%	ROA	-169.22%	Short Interest	0.71M	Perf Year	-23.87%
Cash/sh	0.25	P/C	4.72	EPS next 5Y	-	ROE	-192.32%	52W Range	0.51 - 5.01	Perf YTD	3.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-314.53%	52W High	-76.45%	Beta	1.20
Dividend TTM	-	Quick Ratio	6.11	Sales past 5Y	0.00%	Gross Margin	-	52W Low	131.37%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	6.11	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	58.02	Volatility	16.00% 10.49%
Employees	3	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	14.08
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	44.13%	Payout	-	Rel Volume	2.32	Prev Close	1.25
Sales Surprise	-	EPS Surprise	-30.56%	Sales Q/Q	-	Earnings	Feb 26	Avg Volume	345.01K	Price	1.18
SMA20	12.39%	SMA50	3.86%	SMA200	-8.73%	Trades		Volume	799,039	Change	-5.60%

Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks) -5.60%
Mar-13-25 08:00AM	MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain (ACCESSWIRE) +25.00%
Mar-04-25 08:00AM	MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain (ACCESSWIRE)
07:45AM	EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain (Benzinga)
Dec-27-24 02:56AM	Memecoin Degens Raise Millions for Rare Cancer Research After a Fathers Plea (CoinDesk)
09:00AM	Loading…
Dec-19-24 09:00AM	MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development (ACCESSWIRE)
08:25AM	EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment (Benzinga)
Dec-10-24 08:30AM	MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End (ACCESSWIRE)
08:15AM	EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain (Benzinga)
Nov-20-24 07:44AM	MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site (ACCESSWIRE) -9.64%
Oct-29-24 10:57AM	MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials (GuruFocus.com) +10.19%
Oct-28-24 01:41PM	MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain (Benzinga) +21.71%
07:30AM	MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain (ACCESSWIRE)
Oct-27-24 05:34PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024 (Market Exclusive)
Oct-21-24 07:30AM	MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study (ACCESSWIRE)
07:30AM	Loading…
Sep-27-24 07:30AM	MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024 (ACCESSWIRE) +8.41%
Sep-19-24 09:00AM	MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025 (News Direct)
Sep-18-24 07:00AM	MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 (ACCESSWIRE) -10.69%
Sep-11-24 07:30AM	MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA (ACCESSWIRE) +9.30%
Aug-26-24 08:00AM	MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study (ACCESSWIRE) +14.05%
Aug-19-24 07:30AM	MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End (ACCESSWIRE) -7.77%
Aug-12-24 08:30AM	Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman (GlobeNewswire)
08:00AM	MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor (ACCESSWIRE)
Aug-05-24 09:40AM	PayPal, Kellanova upgraded: Wall Street's top analyst calls (The Fly)
Jul-25-24 03:24PM	Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data (Benzinga) +28.81%
07:00AM	MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2's Selective NMDA Binding Mechanism of Action (ACCESSWIRE)
Jul-22-24 12:56PM	Why Is MIRA Pharmaceuticals (MIRA) Stock Up 318% Today? (InvestorPlace) +627.35%
10:31AM	Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders (Benzinga)
08:00AM	MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance (ACCESSWIRE)
Jul-15-24 07:00AM	Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC (ACCESSWIRE) +25.59%
08:30AM	Loading…
Jun-24-24 08:30AM	MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing (PR Newswire)
Jun-10-24 08:30AM	Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year (PR Newswire)
May-29-24 08:45AM	Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance (PR Newswire)
May-21-24 08:45AM	MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog (PR Newswire) +20.00%
May-20-24 08:00AM	Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog (PR Newswire) +29.77%
May-13-24 09:53PM	MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q1 2024 (InvestorPlace)
Apr-02-24 08:00AM	Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission (PR Newswire)
Apr-01-24 02:53PM	MIRA Stock Earnings: Mira Pharmaceuticals Beats EPS for Q4 2023 (InvestorPlace)
Mar-21-24 11:04AM	MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor (PR Newswire)
Mar-08-24 08:19AM	Why Is Mira Pharmaceuticals (MIRA) Stock Up 52% Today? (InvestorPlace) +65.28%
Feb-05-24 08:30AM	MIRA Pharmaceuticals Provides Corporate Update (PR Newswire) +45.99%
Dec-04-23 08:00AM	MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations (PR Newswire) -5.26%
Nov-29-23 08:00AM	MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80% (PR Newswire)
Nov-21-23 10:42AM	MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time (PR Newswire) -16.13%
10:09AM	MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a (PR Newswire)
Nov-20-23 08:00AM	MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2 (PR Newswire) +40.06%
Oct-26-23 07:23AM	MIRA: Developing Cannabis with Benefits and Without Side Effects (Zacks) +5.38%
Sep-18-23 08:30AM	MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot (PR Newswire) +38.80%
Sep-05-23 08:31AM	MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts (PR Newswire)
Aug-31-23 08:31AM	MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit (PR Newswire)
Aug-29-23 11:39AM	MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time (PR Newswire)
Aug-09-23 09:35AM	MIRA Pharmaceuticals, Inc. Discusses Potential of Revolutionary THC Analog Drug, MIRA1a, with The Stock Day Podcast (ACCESSWIRE)
Aug-03-23 02:40PM	MIRA Pharmaceuticals debuts on the Nasdaq with plans to revolutionize medicinal CBD and THC (News Direct)

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company engages in developing its product candidate, MIRA1a, as a synthetic cannabinoid analog for treating anxiety & chronic pain by targeting the cannabinoid type 1 and type 2 (CB1 and CB2) receptors. MIRA Pharmaceuticals was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aminov Erez	Chief Executive Officer	Nov 19 '24	Sale	1.39	55,410	77,020	1,105,790	Nov 27 04:15 PM
Aminov Erez	Chief Executive Officer	Nov 20 '24	Sale	1.27	44,590	56,629	1,061,200	Nov 27 04:15 PM
Erez Aminov	Affiliate	Nov 19 '24	Proposed Sale	1.41	100,000	141,000		Nov 19 05:58 PM
Brian McNulty	affiliate	Sep 04 '24	Proposed Sale	1.80	10,000	18,000		Sep 04 08:20 PM
McNulty Brian Patrick	10% Owner	Aug 28 '24	Sale	1.96	200,000	392,000	2,540,270	Aug 30 04:05 PM
Aminov Erez	Chief Executive Officer	May 21 '24	Buy	0.94	8,700	8,176	382,200	May 22 05:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Mira Pharmaceuticals Inc

Upgrade your FINVIZ experience